The Valley Desk

Clinical trial reportJournal for immunotherapy of cancerPublished

Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Bristol Myers Squibb, Thomas Jefferson University. Affiliation source

Publication record

Type
Clinical trial report
Venue
Journal for immunotherapy of cancer
Published
Subject terms
Humans; Colorectal Neoplasms; Pancreatic Neoplasms; Receptors, CCR5; Antineoplastic Combined Chemotherapy Protocols; Adult; Aged; Aged, 80 and over; Middle Aged; Female; Male; Receptors, CCR2
PubMed ID
41571299
PubMed Central ID
PMC12829384
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal